RNA
Atrium Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Atrium Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Largest filed tie
0
filed ties
No thesis.
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Expected move
No implied move.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Atrium Therapeutics, Inc.'s 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Atrium Therapeutics, Inc.'s 6 closest co-movers, 1 shares that code.
News
Atrium Therapeutics, Inc.
8.56
pre 8.80 +2.92%
No trades yet today.
No trades yet today.
| Manager | Value | % base | |
|---|---|---|---|
| Sessa Capital IM | $20.2M | 9.87% | +172.04% |
| T. Rowe Price | $19.8M | 9.69% | −5.17% |
| BlackRockindex-like | $19.5M | 9.52% | +20.09% |
| Susquehanna International | $11.3M | 5.53% | −18.40% |
| Vanguardindex-like | $9.8M | 4.81% | +16.58% |
| Manager | Value | % base | |
|---|---|---|---|
| Sessa Capital IM | $20.2M | 9.87% | +172.04% |
| T. Rowe Price | $19.8M | 9.69% | −5.17% |
| BlackRockindex-like | $19.5M | 9.52% | +20.09% |
| Susquehanna International | $11.3M | 5.53% | −18.40% |
| Vanguardindex-like | $9.8M | 4.81% | +16.58% |
Bull1
Bear1